Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598433 | 1.00 | CYP2D6 (0.47) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| Ammonia Solution, Strong SCHEMBL4506501 | 0.81 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL9009194 | 0.72 | CYP2D6 (0.55) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL20183365 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL20183463 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL20183464 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL3178883 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL3178880 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL20183363 | 0.72 | CYP2D6 (0.50) | CYP2D6NPSR1GPR55MC4ROPRM1 | |
| SCHEMBL23186699 | 0.72 | GAA (0.49) | CYP2D6MC4RCYP3A4CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| WO-2020259584-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | CYP2D6 2125/4885NPSR1 4094/4885GPR55 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.